NZ254267A - Animal vaccines comprising a pseudorabies virus having a mutation in its gp50 gene - Google Patents
Animal vaccines comprising a pseudorabies virus having a mutation in its gp50 geneInfo
- Publication number
- NZ254267A NZ254267A NZ254267A NZ25426793A NZ254267A NZ 254267 A NZ254267 A NZ 254267A NZ 254267 A NZ254267 A NZ 254267A NZ 25426793 A NZ25426793 A NZ 25426793A NZ 254267 A NZ254267 A NZ 254267A
- Authority
- NZ
- New Zealand
- Prior art keywords
- virus
- gene
- mutants
- vaccine
- virol
- Prior art date
Links
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 title claims abstract description 143
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 title claims abstract description 143
- 229960005486 vaccine Drugs 0.000 title claims abstract description 59
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 title claims abstract description 18
- 230000035772 mutation Effects 0.000 title claims abstract description 15
- 241001465754 Metazoa Species 0.000 title abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 208000009305 pseudorabies Diseases 0.000 claims abstract description 25
- 208000031295 Animal disease Diseases 0.000 claims abstract description 18
- 239000000427 antigen Substances 0.000 claims abstract description 13
- 102000036639 antigens Human genes 0.000 claims abstract description 13
- 108091007433 antigens Proteins 0.000 claims abstract description 13
- 101150118312 gp63 gene Proteins 0.000 claims abstract description 13
- 238000003780 insertion Methods 0.000 claims abstract description 13
- 230000037431 insertion Effects 0.000 claims abstract description 12
- 108010059485 brain synaptic membrane glycoprotein gp 50 Proteins 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 112
- 208000015181 infectious disease Diseases 0.000 claims description 63
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 230000002458 infectious effect Effects 0.000 claims description 22
- 238000012217 deletion Methods 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 17
- 230000005540 biological transmission Effects 0.000 claims description 16
- 210000002845 virion Anatomy 0.000 claims description 15
- 244000052769 pathogen Species 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 229940126580 vector vaccine Drugs 0.000 claims description 3
- 101150030521 gI gene Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 60
- 239000013612 plasmid Substances 0.000 description 44
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 39
- 239000012634 fragment Substances 0.000 description 32
- 241000282887 Suidae Species 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 230000001018 virulence Effects 0.000 description 20
- 239000013598 vector Substances 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 206010037660 Pyrexia Diseases 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000002238 attenuated effect Effects 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 206010053759 Growth retardation Diseases 0.000 description 9
- 231100000001 growth retardation Toxicity 0.000 description 9
- 230000000926 neurological effect Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 102000004594 DNA Polymerase I Human genes 0.000 description 8
- 108010017826 DNA Polymerase I Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 231100000518 lethal Toxicity 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 231100000219 mutagenic Toxicity 0.000 description 7
- 230000003505 mutagenic effect Effects 0.000 description 7
- 241001529453 unidentified herpesvirus Species 0.000 description 7
- 206010033799 Paralysis Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 241000710777 Classical swine fever virus Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 4
- 208000001726 Classical Swine Fever Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 206010035148 Plague Diseases 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 241000607479 Yersinia pestis Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000711493 Porcine respiratory coronavirus Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 101150015940 gL gene Proteins 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000003363 transsynaptic effect Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 101150033033 28K gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108050002093 Haemagglutinin-neuraminidases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000750042 Vini Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006033 mucosulfatidosis Diseases 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92202096 | 1992-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ254267A true NZ254267A (en) | 1996-08-27 |
Family
ID=8210764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ254267A NZ254267A (en) | 1992-07-09 | 1993-07-08 | Animal vaccines comprising a pseudorabies virus having a mutation in its gp50 gene |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5674500A (enExample) |
| EP (1) | EP0654086B1 (enExample) |
| JP (1) | JPH07509127A (enExample) |
| KR (1) | KR100341994B1 (enExample) |
| CN (1) | CN1124159C (enExample) |
| AT (1) | ATE189000T1 (enExample) |
| AU (1) | AU684252B2 (enExample) |
| CA (1) | CA2139507C (enExample) |
| DE (1) | DE69327656T2 (enExample) |
| DK (1) | DK0654086T3 (enExample) |
| ES (1) | ES2143507T3 (enExample) |
| HU (1) | HU220099B (enExample) |
| NZ (1) | NZ254267A (enExample) |
| PL (1) | PL174219B1 (enExample) |
| RU (1) | RU2158308C2 (enExample) |
| TW (1) | TW289731B (enExample) |
| WO (1) | WO1994001573A1 (enExample) |
| ZA (1) | ZA934882B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69201441T3 (de) * | 1991-06-06 | 2008-12-04 | Boehringer Ingelheim Vetmedica Gmbh | Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits. |
| US6007825A (en) * | 1991-12-23 | 1999-12-28 | American Cyanamid Company | Serpulina hyodysenteriae vaccine comprising a tly gene mutant |
| US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| US6592873B1 (en) | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
| US6773908B1 (en) * | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| US6380376B1 (en) * | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| EP0689603A1 (en) * | 1993-03-19 | 1996-01-03 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| EP0659885A1 (en) * | 1993-12-21 | 1995-06-28 | Akzo Nobel N.V. | Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity |
| EP0693551A1 (en) | 1994-07-18 | 1996-01-24 | Akzo Nobel N.V. | gD-negative bovine herpesvirus mutant, capable of direct cell-to-cell transmission |
| EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
| JP3961222B2 (ja) * | 1999-03-08 | 2007-08-22 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Ｐｒｒｓｖワクチン |
| EP1183332B1 (en) * | 1999-04-22 | 2010-07-14 | United States Department Of Agriculture | Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
| CA2509494A1 (en) * | 2002-12-11 | 2004-06-24 | University Of Massachusetts | Method of introducing sirna into adipocytes |
| CA2571452A1 (en) * | 2004-06-18 | 2006-01-26 | Regents Of The University Of Minnesota | Identifying virally infected and vaccinated organisms |
| US7632636B2 (en) * | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
| PL1904631T3 (pl) | 2005-06-24 | 2012-10-31 | Univ Minnesota | Wirusy PRRS, klony zakaźne, ich mutanty i sposoby stosowania |
| CN101081298A (zh) * | 2007-06-26 | 2007-12-05 | 陈少莺 | 一种猪伪狂犬病新型亚单位疫苗制备方法 |
| JP5619004B2 (ja) * | 2008-08-25 | 2014-11-05 | ベーリンガーインゲルハイム フェトメディカ インコーポレイテッド | 高病原性ブタ繁殖・呼吸障害症候群（ｈｐｐｒｒｓ）のワクチン |
| CN101457215B (zh) * | 2008-12-01 | 2010-11-17 | 华中农业大学 | 重组猪伪狂犬病毒-猪繁殖与呼吸综合征病毒-猪圆环病毒基因工程毒株及应用 |
| TWI627281B (zh) * | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物 |
| RU2439150C1 (ru) * | 2010-11-16 | 2012-01-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии | Штамм "ас-21/07" вируса ауески для изготовления вакцинных и диагностических препаратов |
| AU2012217170B2 (en) | 2011-02-17 | 2016-07-28 | Boehringer Ingelheim Vetmedica Gmbh | Commercial scale process for production of PRRSV |
| WO2012110489A2 (en) | 2011-02-17 | 2012-08-23 | Boehringer Ingelheim Vetmedica Gmbh | Novel european prrsv strain |
| WO2013017568A1 (en) | 2011-07-29 | 2013-02-07 | Boehringer Ingelheim Vetmedica Gmbh | INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF |
| US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
| US9579373B2 (en) | 2013-03-15 | 2017-02-28 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
| CN104250640A (zh) * | 2014-08-22 | 2014-12-31 | 普莱柯生物工程股份有限公司 | 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用 |
| CN105087506B (zh) * | 2015-03-20 | 2020-06-30 | 普莱柯生物工程股份有限公司 | 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859587A (en) * | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
| EP0231209B1 (en) * | 1985-07-29 | 1991-02-06 | The Upjohn Company | Virus vaccine |
| US5352575A (en) * | 1985-10-04 | 1994-10-04 | The Upjohn Company | Pseudorabies virus protein |
| US4999296A (en) * | 1986-04-29 | 1991-03-12 | Novagene, Inc. | Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same |
| NL8902087A (nl) * | 1989-08-17 | 1991-03-18 | Stichting Tech Wetenschapp | Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten. |
| AU658836B2 (en) * | 1990-09-25 | 1995-05-04 | Xenova Research Limited | Viral defective vaccine produced by transcomplementing cell line |
| JPH07500972A (ja) * | 1992-07-30 | 1995-02-02 | アクゾ・ノベル・エヌ・ベー | 非放出性ヘルペスウイルス生ワクチン |
-
1993
- 1993-07-02 TW TW82105279A patent/TW289731B/zh active
- 1993-07-07 ZA ZA934882A patent/ZA934882B/xx unknown
- 1993-07-08 NZ NZ254267A patent/NZ254267A/en unknown
- 1993-07-08 RU RU95105518A patent/RU2158308C2/ru not_active IP Right Cessation
- 1993-07-08 HU HU9500039A patent/HU220099B/hu not_active IP Right Cessation
- 1993-07-08 WO PCT/NL1993/000146 patent/WO1994001573A1/en not_active Ceased
- 1993-07-08 JP JP6503188A patent/JPH07509127A/ja active Pending
- 1993-07-08 KR KR1019950700064A patent/KR100341994B1/ko not_active Expired - Fee Related
- 1993-07-08 AU AU45898/93A patent/AU684252B2/en not_active Ceased
- 1993-07-08 EP EP19930916297 patent/EP0654086B1/en not_active Expired - Lifetime
- 1993-07-08 DK DK93916297T patent/DK0654086T3/da active
- 1993-07-08 CA CA 2139507 patent/CA2139507C/en not_active Expired - Fee Related
- 1993-07-08 DE DE69327656T patent/DE69327656T2/de not_active Expired - Fee Related
- 1993-07-08 PL PL93307049A patent/PL174219B1/pl not_active IP Right Cessation
- 1993-07-08 ES ES93916297T patent/ES2143507T3/es not_active Expired - Lifetime
- 1993-07-08 AT AT93916297T patent/ATE189000T1/de not_active IP Right Cessation
- 1993-07-08 US US08/373,325 patent/US5674500A/en not_active Expired - Fee Related
- 1993-07-09 CN CN93108005A patent/CN1124159C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994001573A1 (en) | 1994-01-20 |
| PL307049A1 (en) | 1995-05-02 |
| DE69327656D1 (de) | 2000-02-24 |
| HUT70986A (en) | 1995-11-28 |
| HU9500039D0 (en) | 1995-03-28 |
| CN1086143A (zh) | 1994-05-04 |
| EP0654086A1 (en) | 1995-05-24 |
| DE69327656T2 (de) | 2000-08-03 |
| ATE189000T1 (de) | 2000-02-15 |
| HU220099B (hu) | 2001-10-28 |
| PL174219B1 (pl) | 1998-06-30 |
| RU95105518A (ru) | 1997-03-27 |
| ZA934882B (en) | 1994-02-03 |
| TW289731B (enExample) | 1996-11-01 |
| CA2139507C (en) | 2005-04-19 |
| KR100341994B1 (ko) | 2002-11-30 |
| US5674500A (en) | 1997-10-07 |
| CA2139507A1 (en) | 1994-01-20 |
| AU684252B2 (en) | 1997-12-11 |
| AU4589893A (en) | 1994-01-31 |
| ES2143507T3 (es) | 2000-05-16 |
| RU2158308C2 (ru) | 2000-10-27 |
| JPH07509127A (ja) | 1995-10-12 |
| EP0654086B1 (en) | 2000-01-19 |
| CN1124159C (zh) | 2003-10-15 |
| DK0654086T3 (da) | 2000-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0654086B1 (en) | Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants | |
| DK172285B1 (da) | Deletionsmutant af et herpesvirus og vaccine indeholdende dette virus | |
| US6387376B1 (en) | Recombinant vaccine containing feline herpes virus type 1 particularly for treating feline infectious peritonitis | |
| JP2000512844A (ja) | ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン | |
| JP2000512264A (ja) | カレ病、狂犬病、タイプ２のパラインフルエンザに対するイヌヘルペスウイルスをベースにした組換え生ワクチン | |
| US5626850A (en) | Non-shedding live herpesvirus vaccine | |
| US7060282B1 (en) | Attenuated equine herpesvirus | |
| JP3529134B2 (ja) | 組換えネコヘルペスウイルスのベクターワクチン | |
| NZ253188A (en) | Vaccines and mutants in relation to infectious bovine rhinotracheitis virus | |
| NL8902087A (nl) | Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten. | |
| WO1995007987A2 (en) | Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor | |
| AU784310B2 (en) | Recombinant infectious laryngotracheitis virus vaccine | |
| AU738684B2 (en) | Recombinant equine herpesvirus type 1 (EHV-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine | |
| WO1998003635A1 (en) | Regions nonessential for the proliferation of avipoxviruses, and recombinant avipoxviruses and vaccines prepared with the use of the same | |
| US20020155131A1 (en) | Recombinant equine herpesvirus type 1 (EHV-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine | |
| WO1998004710A9 (en) | Live recombinant bhv/brsv vaccine | |
| WO1998004710A2 (en) | Live recombinant bhv/brsv vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |